Quantcast

NEW CERAMENT™ App Available on App Store

May 1, 2014

Features clinical indications for CERAMENT™|BONE VOID FILLER.

Lund, Sweden (PRWEB) May 01, 2014

BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced the release of a new iPad® app called, CERAMENT™, now available for download from iTunes®. The CERAMENT™ app is designed to impart valuable information on the indications and clinical experience with CERAMENT™|BONE VOID FILLER. The app runs off the cloud, allowing for real-time, seamless updates of new clinical experiences, case studies, and other pertinent information.

The app allows users to:

  •     Access clinical case studies and surgical x-ray images by area of the anatomy
  •     Follow detailed product mixing and handling instructions and view mixing video
  •     Explore the mechanism of action of CERAMENT™
  •     View product literature, pictures, and support tools within the app library

“The new CERAMENT™ app is a simple yet powerful tool that offers important connectivity to the surgeons who utilize our unique product platform,” said Lloyd Diamond, CEO of BONESUPPORT. “The app delivers both convenience and confidence by providing detailed product instructions alongside indication specific clinical experiences with easy to use navigation and real-time updates.”

CERAMENT™|BONE VOID FILLER is FDA cleared as a filler for gaps and bone voids for orthopedic applications. CERAMENT™ is naturally resorbed by the body and is replaced by natural bone during the healing process. Studies have shown that new bone remodels within 6-12 months following treatment with CERAMENT™|BONE VOID FILLER.

The CERAMENT™ app is available now from the iTunes Store.

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and close to 9,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit http://www.bonesupport.com.

Press Inquiries:

Offer Nonhoff

Chief Financial Officer

Offer.Nonhoff(at)bonesupport(dot)com

Phone +46 46 286 53 60

PR 0354-01 EN

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/05/prweb11811245.htm


Source: prweb



comments powered by Disqus